Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan

Objectives: To estimate appropriate dose-volume parameters for avoidance of pneumonitis in use of chemoradiotherapy and durvalumab for treatment of lung cancer. Materials and methods: Patients with non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab at 9 cente...

Full description

Bibliographic Details
Main Authors: Yoshiko Oshiro, Masashi Mizumoto, Yuta Sekino, Kazushi Maruo, Toshiki Ishida, Taisuke Sumiya, Masatoshi Nakamura, Ayako Ohkawa, Daichi Takizawa, Toshiyuki Okumura, Yoshio Tamaki, Hideyuki Sakurai
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Radiotherapy
Durvalumab
Pneumonitis
Dose-volume histogram
Proton therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630821000537

Internet

http://www.sciencedirect.com/science/article/pii/S2405630821000537

Similar Items